tophaceous gout, chronic gout, monosodium urate crystals OR monosodium urate burden OR tophi OR monosodium urate volume OR flares OR pain OR distress OR death OR disability OR function). Human studies in English were considered. Titles, abstracts and full articles were reviewed. A manual search of secondary sources was conducted. Key gaps identified were considered throughout 2020 when reviewing emerging articles and presentations. Data extraction was conducted by both authors; data presented represents consensus.

Results: Of 344 articles, 81 titles/abstracts met screening inclusion criteria (24%) in the 2019 search; review of the full manuscript led to 41 articles selected (51%). Additionally, 3 key papers and 2 ACR 2020 presentations were identified through 2020. DECT is highly reliable with inter-class correlation coefficients >0.9. DECT has content validity. Dalbeth (2015) showed DECT and X-Rays findings correlated in tophaceous patients, $r=0.70$, $p<0.001$. Hand function correlates with DECT burden, with $r^2=0.59$, $p=0.024$ (Dalbeth 2007). Dalbeth (2017) showed DECT associated with greater flares at 3 and 12 months ($p<0.01$) in 152 patients. Pascart (2018) confirmed that subjects with flares had nearly doubled DECT feet volumes (0.9 vs 2.1 cm^3 , $p=0.05$) versus those not flaring. Dalbeth (2017) showed abnormal DECT scans occurred in 47% of patients with normal uric acid ($<6.0\text{ mg/dL}$) without palpable tophi and in 90% with elevated uric acid and palpable tophi. DECT is very sensitive to change (Araujo 2015) with 95% volume reduction in 152 patients on pegloticase treated up to 12 months. Three studies show DECT is correlated to cardiovascular risk factor prevalence (Pascart 2020, Gamala 2018, Lee 2017). Marty-Ané reported that DECT volume predicts mortality (Marty-Ané ACR 2020). Limited evidence from 3 studies suggests that the minimum important volume for DECT is 1.0 cm^3 at feet and ankles, including Pascart 2020.

Conclusion: DECT imaging is highly reliable, has evidence for content validity and is highly sensitive to change. DECT appears to predict future gout flares, cardiovascular risk factor prevalence and mortality. Minimum important DECT volume approximates 1.0 cm^3 . DECT requires further study but appears to be a relevant outcome for clinical trials and staging gout patients.

REFERENCES:

Authors	Journal, Volume, Issue	Year
Araujo, E. G., Bayat, S., et al.	<i>RMD Open</i>	2015
Dalbeth, N., Nicolau, S., et al.	<i>Ann Rheum Dis</i> , 77(3)	2017
Dalbeth, N., Aati, O., et al.	<i>Ann Rheum Dis</i> , 74(6)	2015
Dalbeth, N., Collis, J., et al.	<i>Rheumatology</i> , 46(12)	2007
Gamala, M., Linn-Rasker, S. P., et al.	<i>Clinical Rheumatol</i> , 37(7)	2018
Lee, K., Ryu, S., et al.	<i>Clinical Rheumatol</i> , 37	2017
Marty-Ané, A., Norbert, L., et al.	<i>Arthritis Rheumatol</i> 72 (supp 10) [abstract #0954] ACR 2020.	2020
Pascart, T., Ramon, A., et al.	<i>J Clin Med</i> , 9(5)	2020
Pascart, T., Capon, B., et al.	<i>Arthritis Res and Therapy</i> , 20(1)	2018
Perez-Ruiz, F., Martínez-Indart, L., et al.	<i>Ann Rheum Dis</i> , 73(1)	2013
Richette, P., Doherty, M., et al.	<i>Ann Rheum Dis</i> , 79(1)	2020
Vincent, Z., Gamble, G., et al.	<i>J Rheumatol</i> , 44 (3)	2017

Disclosure of Interests: Sally Stauder: None declared, Paul M. Peloso Shareholder of: Horizon Therapeutics plc, Employee of: Horizon Therapeutics plc.
DOI: 10.1136/annrheumdis-2021-eular.872

POS1126

PREVALENCE OF HYPOPHOSPHATASIA IN ADULT RHEUMATOLOGY PATIENTS SCREENED BY LOW LEVELS OF ALKALINE PHOSPHATASE

P. Karakostas¹, R. Dolscheid-Pommerich², M. Hass³, P. Brossart⁴, V. Schäfer⁴.

¹University Hospital of Bonn, Germany, Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, Bonn, Germany;

²University Hospital of Bonn, Germany, Institute of Clinical Chemistry and Clinical Pharmacology, Bonn, Germany; ³Center for Blood Coagulation Disorders and Transfusion Medicine Bonn, Germany, Center for Blood Coagulation Disorders and Transfusion Medicine Bonn, Germany, Bonn, Germany; ⁴University Hospital of Bonn, Germany, Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, Bonn, Germany

Background: Hypophosphatasia (HPP) is a genetic disease caused by one or more mutations in the alkaline phosphatase (ALP) gene, which encodes tissue-specific ALP and affects the mineralization process. Accordingly, arthralgia, fractures, and dental abnormalities have been reported in adults, and fatal courses in children. This metabolic disorder is commonly misdiagnosed with other more prevalent bone diseases due to its low prevalence and lack of recognition (i.e. chondrocalcinosis). However, no epidemiological studies on the prevalence of HPP in the rheumatological patient population have been available to date.

Objectives: To identify the prevalence of HPP in rheumatological patients screened for persistent low levels of ALP and association with mutations in the ALP gene.

Methods: All adult rheumatology patients were screened for pathological low levels of ALP ($< 35\text{ IU/L}$) between January 1, 2017 and June 30, 2019 at the Department of Rheumatology, Clinic of Internal Medicine III, University Hospital Bonn, Germany. Medical files of patients with pathological low ALP levels were then reviewed for clinical signs and symptoms as well as results of genetic testing for HPP (full sequencing using Next Generation Sequencing).

Results: In total, 2,289 rheumatology patients were screened for low ALP levels. In 60 patients (2.62 %), pathological low ALP levels were identified, while in 30 of these (1.31 %), persistent low ALP levels were detected. In 19 of the 30 patients, genetic tests for ALPL gene mutations were done. Seven out of 19 patients (36.84 %) had HPP-related symptoms (fracture, dental abnormalities) with normal bone densitometry, while four of these patients (21.05 %) had a history of fracture and three patients (15.78 %) showed dental abnormalities. In addition to the typical HPP signs and symptoms, 13 patients (68.42%) showed mutations in the ALPL gene. One of the ALP mutations was found to be a novel genetic variant, classified as pathological. Interestingly, no association with chondrocalcinosis was detected.

Conclusion: In summary, it can be concluded that HPP is an under-diagnosed condition with a higher proportion of affected rheumatologic patients than previously thought (at least 0.56 percent of rheumatologic patients vs. 0.01 percent in a Spanish healthy population). If we replicate these numbers for the German population (83 million, 5 percent of whom suffer from rheumatic conditions) the yield is approximately 4.15 million. This possibly indicates that 23,240 potential cases of HPP are currently not diagnosed. Therefore, implementation of a protocol in clinical practice to prevent underdiagnosis of HPP and to treat this disease appropriately is essential.

REFERENCES:

- [1] García-Fontana C, Villa-Suárez JM, Andújar-Vera F et al (2019) Epidemiological, Clinical and Genetic Study of Hypophosphatasia in A Spanish Population: Identification of Two Novel Mutations in The Alpl Gene. *Sci Rep*. <https://doi.org/10.1038/s41598-019-46004-2>
- [2] Mornet E, Yvard A, Taillandier A et al (2011) A molecular-based estimation of the prevalence of hypophosphatasia in the European population. *Ann Hum Genet* 75:439–445. <https://doi.org/10.1111/j.1469-1809.2011.00642.x>

Figure 1.

Flow chart of identification of potential hypophosphatasia (HPP) patients from an adult rheumatology population. Threshold alkaline phosphatase $< 35\text{ IU/L}$ at 37 °C. ALP: alkaline phosphatase

Disclosure of Interests: Pantelis Karakostas: None declared, Ramona Dolscheid-Pommerich: None declared, Moritz Hass: None declared, Peter Brossart: None declared, Valentin Schäfer Speakers bureau: AbbVie, Novartis, BMS, Chugai, Celgene, Medac, Sanofi, Lilly, Hexal, Pfizer, Janssen, Roche, Schire, Onkowsen, Royal College London, Consultant of: Novartis, Chugai, AbbVie, Celgene, Sanofi, Lilly, Hexal, Pfizer, Amgen, BMS, Roche, Gilead, Medac, Grant/research support from: Novartis, Hexal, Lilly, Roche, Celgene, Universität Bonn.

DOI: 10.1136/annrheumdis-2021-eular.1082